TY - JOUR
T1 - Anti-androgen receptor signaling and prostate cancer inhibitory effects of sucrose- and benzophenone-compounds
AU - Wang, Zhe
AU - Lee, Hyo Jeong
AU - Wang, Lei
AU - Jiang, Cheng
AU - Baek, Nam In
AU - Kim, Sung Hoon
AU - Lü, Junxuan
N1 - Funding Information:
This work was supported in part by The Hormel Foundation, Prostate Cancer Foundation, by MRC grant R13-2007-019-00000-0 from Korea Ministry of Education, Science and Technology. The authors thank Todd Schuster for performing flow cytometry analyses.
PY - 2009/5
Y1 - 2009/5
N2 - Purpose: Novel agents that target multiple aspects of androgen receptor (AR) signaling are desirable for chemoprevention and treatment of prostate cancer (PCa). We aimed to identify compounds isolated from medicinal herbs as such drug candidates. Methods: In the LNCaP human androgen sensitive PCa cell model, we tested five compounds purified from Lindera fruticosa Hemsley in the range of 10-50 μM for growth inhibition and AR-prostate specific antigen (PSA) suppressing potency. We determined the relationship between these activities and P53 tumor suppressor protein activation and apoptotic cleavage of PARP. We compared these compounds to the anti-androgen drug Casodex/bicalutamide to identify mechanistic novelty. Results: Among 3 sucrose compounds, beta-D-(3,4-di-sinapoyl)fructofuranosyl-alpha-D-(6-sinapoyl) glucopyranoside decreased AR and PSA mRNA and protein levels in LNCaP cells and inhibited androgen-stimulated AR translocation from the cytosol to the nucleus. This compound also increased P53 Ser15 phosphorylation and PARP cleavage in LNCaP cells, but required higher dosage than for suppressing AR-PSA. Interestingly, this compound did not inhibit the growth of RWPE-1 non-transformed prostate epithelial cells. The benzophenone compound 2-methoxy-3,4-(methylenedioxy)benzophenone suppressed PSA and AR in LNCaP cells without apoptosis. Conclusions: Our data support novel anti-AR actions of these herbal compounds distinct from Casodex and merit further investigation as drug candidates.
AB - Purpose: Novel agents that target multiple aspects of androgen receptor (AR) signaling are desirable for chemoprevention and treatment of prostate cancer (PCa). We aimed to identify compounds isolated from medicinal herbs as such drug candidates. Methods: In the LNCaP human androgen sensitive PCa cell model, we tested five compounds purified from Lindera fruticosa Hemsley in the range of 10-50 μM for growth inhibition and AR-prostate specific antigen (PSA) suppressing potency. We determined the relationship between these activities and P53 tumor suppressor protein activation and apoptotic cleavage of PARP. We compared these compounds to the anti-androgen drug Casodex/bicalutamide to identify mechanistic novelty. Results: Among 3 sucrose compounds, beta-D-(3,4-di-sinapoyl)fructofuranosyl-alpha-D-(6-sinapoyl) glucopyranoside decreased AR and PSA mRNA and protein levels in LNCaP cells and inhibited androgen-stimulated AR translocation from the cytosol to the nucleus. This compound also increased P53 Ser15 phosphorylation and PARP cleavage in LNCaP cells, but required higher dosage than for suppressing AR-PSA. Interestingly, this compound did not inhibit the growth of RWPE-1 non-transformed prostate epithelial cells. The benzophenone compound 2-methoxy-3,4-(methylenedioxy)benzophenone suppressed PSA and AR in LNCaP cells without apoptosis. Conclusions: Our data support novel anti-AR actions of these herbal compounds distinct from Casodex and merit further investigation as drug candidates.
UR - http://www.scopus.com/inward/record.url?scp=63949088403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63949088403&partnerID=8YFLogxK
U2 - 10.1007/s11095-009-9833-2
DO - 10.1007/s11095-009-9833-2
M3 - Article
C2 - 19266268
AN - SCOPUS:63949088403
SN - 0724-8741
VL - 26
SP - 1140
EP - 1148
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 5
ER -
